---
title: "Sofinnova Closes €82M MD Start IV to Build Medtech Companies"
description: "Sofinnova Partners closed its oversubscribed €82M MD Start IV fund to create six to eight medtech companies across Europe and the United States over five years."
date: 2026-09-28T00:00:00.000Z
source: https://venturecapitaltracker.com/2026-sofinnova-md-start-iv-82m-final-close
---

# Sofinnova Closes €82M MD Start IV to Build Medtech Companies

> Sofinnova Partners closed its oversubscribed €82M MD Start IV fund to create six to eight medtech companies across Europe and the United States over five years.

Sofinnova Partners has reached the **€82 million final close of Sofinnova MD Start IV**, an oversubscribed vehicle designed to create medtech companies rather than wait for established startups to seek funding.

The firm plans to launch **six to eight companies across Europe and the United States over five years**, supporting them from inception through clinical and operational milestones.

## The fund at a glance

- **Fund:** Sofinnova MD Start IV
- **Final close:** €82 million
- **Status:** Oversubscribed final close
- **Strategy:** Medtech company creation
- **Planned portfolio:** Six to eight new companies
- **Geography:** Europe and the United States
- **Deployment period:** Five years
- **Limited partners:** Not disclosed
- **Manager:** Sofinnova Partners

Sofinnova announced the close on September 28, 2026 in its [official release](https://sofinnovapartners.com/news/sofinnova-partners-closes-oversubscribed-82-million-sofinnova-md-start-iv-fund-to-create-the-next-generation-of-medtech-companies).

## This is a company-creation fund

MD Start does not operate like a conventional fund that primarily selects from externally founded companies. Sofinnova describes the strategy as building businesses from the ground up with clinicians, engineers and scientists.

That can involve identifying a clinical problem, licensing or developing intellectual property, recruiting management and financing a company through early technical and clinical milestones. The model places more operating responsibility on the fund manager, but it may also give the fund greater influence over company design and initial ownership.

The €82 million pool implies substantial concentration: only six to eight new ventures are planned. Dividing the headline fund size by that target produces a gross average of roughly €10 million to €14 million per company, but that is not a disclosed check size. Management fees, reserves, follow-on allocation and uneven investment sizes mean actual initial checks could differ materially.

## Fund IV is about 30% larger than Fund III

Sofinnova MD Start III closed at **€63 million** and invested across six companies. The new €82 million fund is approximately 30% larger.

Sofinnova says the six Fund III companies have collectively raised more than €140 million in follow-on financing. Portfolio examples cited by the firm include LimFlow, acquired by Inari Medical for up to $415 million; PreCARDIA, acquired by Abiomed; CorWave; BrightHeart; and Moon Surgical.

Those examples show what the strategy is trying to achieve, but the follow-on total and operating milestones are manager-reported. They do not disclose Fund III's realized returns, ownership levels or net performance to limited partners.

## What the announcement does not disclose

The firm called MD Start IV oversubscribed, but did not disclose its original target, hard cap or the names of participating limited partners. Investors therefore cannot determine from the announcement how far the close exceeded target or how the LP base changed.

Sofinnova also did not publish its expected initial check range, reserve policy, management fees or carried-interest terms. The announcement is a confirmed final close, but it is not a full fund-economics disclosure.

## Why the model fits medtech

Medtech startups often face a difficult gap between academic validation and institutional venture readiness. They may need prototype development, regulatory planning, clinical study design, quality systems and specialized leadership before a conventional Series A becomes possible.

A dedicated company-creation fund can finance and coordinate that work earlier. The tradeoff is that building companies internally is operationally intensive and limits the number of projects a team can manage simultaneously.

Sofinnova says the strategy is led by partners Anne Osdoit, Cécile Dupont and Mano Iyer, with a wider team of principals, analysts and venture partners. The firm manages more than €4 billion across its broader life-sciences platform.

## Bottom line

Sofinnova MD Start IV is a confirmed **€82 million final close**, not merely a target or first close. Its editorial importance comes from the concentrated company-creation model: the fund plans to build only six to eight medtech businesses over five years. The main missing information is the LP roster and fund economics, both of which remain undisclosed.

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.